341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)

• Lawrence Karsh,
• Sreenivas Adurthi,
• Rahul Aggarwal,
• Mark Linch,
• Dan Costin,
• Jingsong Zhang,
• Paul Monk,
• Stefani Corsi-Travali,
• Adedayo Adedoyin

Affiliations

Lawrence Karsh

Aff3 The Urology Center of Colorado Denver CO USA

Sreenivas Adurthi

Aff686 grid.464802.cAurigene Discovery Technologies Limited Bangalore Karnataka India

Rahul Aggarwal

Aff1 0000 0001 2297 6811grid.266102.1Department of MedicineUniversity of California 1600 Divisadero Street 94115 San Francisco California USA

Mark Linch

Department of Oncology, University College London Cancer Institute, London, UK

Dan Costin

2White Plains Hospital, Center for Cancer Care, White Plains, NY, USA

Jingsong Zhang

3H. Lee Moffitt Cancer Cneter and Research Institute, Tampa, FL, USA

Paul Monk

4The Ohio State University Comprehensive, Columbus, OH, USA

Stefani Corsi-Travali

7BioXcel Therapeutics, Madison, CT, USA

Adedayo Adedoyin

7BioXcel Therapeutics, Madison, CT, USA